Skip to main
LFMD
LFMD logo

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. has demonstrated consistent growth momentum driven primarily by its weight management program, contributing positively to revenue fluctuations in recent quarters. The company's comprehensive telehealth platform positions it favorably for accelerated growth in 2025, bolstered by the strategic addition of accessible weight loss treatments like Wegovy at a significantly reduced cost. Additionally, the integration of various functionalities such as remote testing and digital prescriptions not only enhances patient experience but is also expected to attract a larger subscriber base, thereby potentially increasing overall sales.

Bears say

LifeMD Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include the potential for slower-than-expected growth in telehealth revenue and difficulties in acquiring and retaining new patients, which could hinder the company’s ability to achieve profitability. Additionally, heightened competition within the telehealth market and the risk of potential dilution further exacerbate concerns regarding the company’s financial stability and future performance.

LifeMD (LFMD) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Buy based on their latest research and market trends.

According to 5 analysts, LifeMD (LFMD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.